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Ataxia telangiectasia (AT) is a rare autosomal recessive disorder caused 
by mutation in the Ataxia telangiectasia mutated (ATM) gene. This 
disorder is characterized by progressive cerebellar ataxia, telangiectasia, 
immunodeficiency and a predisposition to leukemia/lymphoma. In this 
study, we investigated a family with a new mutation in ATM, confirmed 
by molecular genetic test.
Materials&Methods
Four members of a family including a symptomatic AT patient, his 
parents and sibling were examined for ATM gene defects at Kerman 
University Hospital, Kerman, Iran in 2016. DNA was extracted from 
peripheral leukocytes and the coding regions and exon-intron boundaries 
of ATM gene were amplified by next-generation sequencing technique. 
The identified mutation was tested in all members of the family. 
Results
Molecular analyses identified a homozygous T to G substitution in 
c.7308-6 position resulting in a novel acceptor splice site in intron 49 of 
the ATM gene in the index patient. Parents and sibling of the proband 
were heterozygous for the same mutation. 
Conclusion
The variant c.7308-6T>G is predicted to be pathogenic due to impaired 
splice site causing exon skipping. This newly found frameshift mutation 
cosegregated as an autosomal recessive trait as expected for Ataxia 
telangiectasia syndrome. 
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Introduction 
Autosomal recessive cerebellar ataxias (ARCAs) 
are a heterogeneous group of neurological 
disorders, characterized by degeneration or 
abnormal development of cerebellum and spinal 
cord. In most patients, onset age is before 30 year. 
The most frequent ARCAs in Caucasian population 
is Friedreich ataxia, ataxia-telangiectasia (AT) and 
early onset cerebellar ataxia with retained tendon 
reflexes. Gait ataxia is the common manifestation 
of these disorders. Other common findings 
include nystagmus, dysarthria, and dysmetria. 
Brain imaging often shows cerebellar atrophy 
or hypoplasia. Age of onset varies widely but is 
frequently in childhood. Intellectual disability, 
peripheral neuropathy, and retinal abnormalities 
may also occur (1). 
Clinical diagnosis is confirmed by magnetic 
resonance imaging (MRI), electrophysiological 
examination, and mutation analysis. Recently, 
molecular genetic has been a powerful approach in 
investigating inherited ataxias (2).
ARCAs have been divided to (1, 3): 1) Congenital 
ataxias which include Joubert syndrome 
(Dysgenesis or agenesis of the vermis and presence 
of molar tooth sign) and Cayman cerebellar 
ataxia (Hypotonia from birth, non-progressive 
truncal and limb ataxia). 2) Metabolic ataxias 
which include ataxia with isolated vitamin E 
deficiency (Very low plasma level of vitamin E 
and normal lipid profile), Abetalipoproteinemia 
(apolipoproteins B deficiency, multiple fat-soluble 
vitamin deficiency and abnormal lipidogram), 
Cerebrotendinous xanthomatosis (Bile acid 
biosynthesis defect, large deposit of cholesterol 
and xanthomas) and Refsum disease (Retinitis 
pigmentosa, deafness, increased phytanic acid 
level in blood and abnormal blood lipids). 3) 
Degenerative and progressive ARCAs which 
include Friedreich ataxia (Ataxia with scoliosis, 
foot deformity, cardiac symptoms, defective 
mitochondrial proteins, absence of telangiectasia 
and normal α-fetoprotein), Mitochondrial 
recessive ataxia syndrome (Mitochondrial DNA 
replicative polymerase defect, Infantile onset 
spinocerebellar ataxia (Mostly Finish heritage 
disease with hypotonia and vision and hearing 
problems), Charlevoix-Saguenay spastic ataxia 
(Early onset, progressive spastic ataxia of all 
limbs with paraplegia, increased tendon reflexes, 
progressive distal wasting, atrophy of the superior 
cerebellar vermis and Retinal hypermyelinated), 
Marinesco-Sjögren syndrome (Ataxia with 
congenital cataract, elevation of serum creatine 
kinase activity, Hypergonadotropic hypogonadism, 
facial dysmorphism and atrophy of the vermis), 
Early onset cerebellar ataxia with retained tendon 
reflexes (Early onset cerebellar ataxia with 
preservation of deep tendon reflexes), Coenzyme 
Q10 deficiency with cerebellar ataxia (Reduced 
levels of coenzyme Q10 in muscle biopsies), and 
Posterior column ataxia and retinitis pigmentosa 
(Posterior column ataxia and retinitis pigmentosa). 
4) DNA repair defects which include ataxia 
telangectasia-like disorder (Different from AT 
based on the genetic data), ataxia with oculomotor 
apraxia-1 (Limb dysmetria, hypoalbuminemia and 
hypercholesterolemia), ataxia with oculomotor 
apraxia-2 (Dystonic posturing with walking and 
elevated values of gamma-globulin, and creatin 
kinase), spinocerebellar ataxia with axonal 
neuropathy (Ataxia with peripheral axonal motor 
and sensory neuropathy, distal muscular atrophy, 
and pes cavus), Xeroderma pigmentosum (Ataxia 
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with skin photosensitivity, early onset skin cancers, 
photophobia, conjunctivitis, keratitis, ectropion 
and entropion), and AT (Progressive ataxia, with 
oculocutaneous telangiectasia, and variable 
immunodeficiency). 
AT is also characterized by sinopulmonary infections, 
radiosensitivity, early aging, chromosomal instability 
and a predisposition to leukemia/lymphoma. It is 
often misdiagnosed in early childhood, before the 
development of a full clinical picture. The first signs 
of the disease are movement disorders with different 
severity. The incidence of AT is 1/40000-100000 
cases, but in several populations, the incidence is 
considerably higher due to founder mutations (4-6). 
The initial clinical description of AT disease 
is reported earlier (7). Three adolescent Czech 
siblings were described with progressive chorea, 
dystonia, and ocular telangiectasia. Later, a 9-yr-
old child was described with progressive cerebellar 
ataxia and bilateral oculocutaneous telangiectasia 
in details (8). The term ataxia telangiectasia was 
introduced in 1958 and recognized as autosomal 
recessive mode of inheritance for the disease (9). 
The disease is sometimes referred to as Boder-
Sedgwick syndrome. Different groups have 
reported case series of AT patients (9-14). 
AT is caused by mutations in the Ataxia 
telangiectasia mutated (ATM) gene, consisting 
of 66 exons, in chromosome 11 (11q22.3). A 
370 kDa protein encoded by ATM gene is an 
important checkpoint kinase which is one of the 
most important controllers of cell cycle checkpoint 
signaling pathways required for cell response to 
DNA damage and for genome stability. Therefore, 
nuclear genomic instability resulting from loss of 
this function is regarded as a major mechanism 
underlying the pathology of AT (5, 15). 
In contrast to ARCAs, autosomal dominant 
cerebellar ataxias are characterized by late onset 
spinocerebellar ataxias and episodic ataxias (16).
In this study, we investigated a family with a new 
mutation in ATM, confirmed by molecular genetic 
test.
Materials & Methods
In 2016, an 8-yr-old boy born of a consanguineous 
marriage was admitted to the Kerman University 
Hospital, Kerman, Iran with the complaints of 
generalized weakness and difficulty to walk. The 
patient had one healthy younger sister of 5 yr 
old. His birth history was uneventful and onset 
of disease occurred about 2 yr of age with loss of 
balance. The progression of the ataxia increasingly 
developed beyond age 5 year. He had ataxic gait, 
abnormal head movements, chorea, myoclonus, 
slurred speech, oculomotor apraxia, neuropathy, 
intention tremor, and hand incoordination. He had 
drooling and frequent experiences of aspiration 
because swallowing was not well coordinated. He 
suffered from frequent respiratory tract infections 
due to low levels of IgG, IgA, and IgG subclasses. 
We found congestions in both eyeballs (Figure 1) 
which appeared between 5 and 6 yr of age and 
nystagmus. He showed also Café au lait spots. His 
intelligence was normal and he was cooperative. 
Writing was affected by age 7 year. Deep tendon 
reflexes were slight but present. 
A genetic counselor explained the objectives and 
aims of the study to participants. Written informed 
consents were obtained from subjects. 
The 5 ml whole blood from subjects’ brachial vein 
in tubes containing 200 µl EDTA was collected to 
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detect any ATM gene mutations. Genomic DNA 
was isolated from leukocytes of the whole blood 
using salt-saturation method (17). In AT work-up, 
the DNA sample of an 8-yr-old affected member 
of the family was screened for the gene defects 
using next-generation sequencing technique. The 
sequencing processes were performed on Illumina 
Hiseq 4000 platform. Sequence reads were 
analyzed using BWA –GATK (18, 19). The other 
family members were screened for the identified 
mutation by PCR and DNA sequencing methods. 
To accomplish this, a 572 bp DNA fragment of the 
ATM gene including intron 49, exon 50 and exon-
intron boundaries were amplified using a forward 
primer 
(5’-AGTGTAAGCAGAGGTGTAAGTTA-3’) 
and a reverse primer 
(5’-CACTGGACCAAGTGCTAGGAATA-3’). 
The PCR reaction was performed using the 
following condition: 30 cycles of denaturation at 94 
°C for 45 sec, annealing at the optimal temperature 
of each primer for 30 sec and extension at 72 °C 
for 30 sec. PCR products were checked on 1% 
agarose gel and taken through an ABI automated 
DNA sequencer (Model: 3730XL).
Results 
Complete blood count, lipid profile, LFT, chest 
X-ray, serum electrolytes, pyruvate, ammonia, 
lactate, levels of vitamins B12 and E were normal 
in the proband, he had low level of IgG, IgA, and 
IgG subclasses, ultrasonogram of whole abdomen 
and ECG were normal. Serum α-fetoprotein was 
high and MRI showed cerebellar atrophy. Four 
members of family including a symptomatic AT 
patient, his parents and sibling were examined for 
ATM gene defects. 
The screening of the ATM gene in patient revealed 
T to G substitution in c.7308-6 position. This 
intronic variant appeared in a homozygous state. 
The asymptomatic sister of the index patient and 
his parents were heterozygous for this mutation 
(Figure 2). Using In Silico Tools for splicing defect 
prediction (20) and Alamut® Visual software 
version 2.8, the variant c.7308-6T>G in intron 
49 is predicted to be pathogenic due to impaired 
splice site. Based on the In Silico prediction tools, 
c.7308-6T>G mutation has moved initial acceptor 
site by 5 bp upstream from its normal position. This 
causes an abnormal splicing process by activation 
of a new cryptic splice acceptor site. The aberrant 
splicing causes exon skipping (Figure 3). 
Fig 1. Ocular telangiectasia in patient. 
115Iran J Child Neurol. Autumn 2018 Vol. 12 No. 4
A Novel Splice Site Mutation of the ATM Gene Associated with Ataxia Telangiectasia
Fig 2. a) Pedigree of the family with AT. The circle indicates female, the square indicates male, and the 
filled square indicates the affected individual. b) The homozygous mutation detected in the ATM gene 
in the patients and heterozygous mutation detected in his parents and sibling. Nucleotide variation is 
indicated by an arrow.
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Discussion 
AT is a complex multisystem disorder caused by a 
mutation in the ATM gene. The ATM gene encodes 
the protein kinase ATM which expressed is mainly 
in the nucleus of lymphocytes, fibroblasts, germ 
cells, and neurons. This protein is the key regulator 
of DNA damage response (21, 22). The AT gene 
was mapped to chromosome 11q22.3 (23).
ATM gene was mutated in AT (24). Since 
then, several mutations in ATM gene including 
truncating mutations, which result in the total 
absence of ATM kinase activity, and missense or 
Fig 3. (a) Ideogram of detected splicing consequences of the c.7308-6 T>G mutation. (b) c.7308-6T>G 
mutation has moved initial acceptor site by 5 bp upstream from its normal position. The window in (b) 
displays the reference and mutated sequences and green vertical bars for 3’ (acceptor) sites. The height of 
each bar is proportional to the maximum possible score. 
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splice site mutations, leading to decreased kinase 
activity have been described (25-29). Up to date, 
more than 400 mutations in the ATM gene have 
been described in AT patients (6). 
We found a new mutation (c.7308-6T>G) in an 
8-yr-old boy with AT who was initially diagnosed 
with loss of balance. Early diagnosis was delayed 
due to the rarity of the disease and also lack of 
obvious clinical symptoms which started at 5 yr 
of age. Several other neurologic and rare disorders 
should be taken into account by  physicians  when 
aiming for the AT diagnosis (2). Some lab tests 
such as gene sequencing as well as the clinical 
features of the disease would assist in differential 
diagnosis (2). The diagnosis was established on 
the basis of clinical features such as progressive 
cerebellar dysfunction, gait and truncal ataxia, 
telangiectasia, head tilting, impaired eye movement, 
immunodeficiency and recurrent sinopulmonary 
infections, dysarthria, slight deep tendon reflexes, 
elevated serum α-fetoprotein and normal height 
and intelligence. 
We conclude that T to G substitution in c.7308-6 
position modifies pattern of splicing leading to a 
five-base insertion in the transcript, which causes 
exon skipping. Splicing site prediction tools gave 
the highest sensitivity scores of 80.5%- 90% for 
initial acceptor site changing. This skipped exon 
is located in FAT domain of protein. Of note, the 
importance of the FAT domain, as a structural 
scaffold or as a protein-binding domain, has been 
reported (30). Exon skipping is a very strong 
evidence (PVS1) of pathogenicity according to the 
ACMG (American College of Medical Genetics 
and Genomics) guidelines (31). Moreover, this 
new mutation also fulfil the supporting criteria 
pp3 (deleterious effect on the gene or gene product 
such as conservation has been supported by various 
computational evidences) and pp4 (patient’s 
phenotype is highly specific for a disease with a 
single genetic etiology) as well as two moderate 
criteria PM1 (Located in a critical and well-
established functional domain e.g. active site of an 
enzyme) and PM2 (Absent from controls in Exome 
Sequencing Project, 1000 Genomes or ExAC) (31).
Therefore, enough lines of evidence are invoked to 
classify this variant as a pathogenic mutation based 
on the ACMG variant classification guidelines. 
In Conclusion, the variant c.7308-6T>G has not 
been reported previously and is predicted to be 
pathogenic due to impaired splice site causing 
exon skipping. However, as a limitation, we did 
not have more cases to confirm this. Therefore, 
further investigation on the functional role and 
clinical impact of novel alteration are proposed.
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